101 Real-world analysis of the impact of pemetrexed in first-line maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic
Saved in:
| Title: | 101 Real-world analysis of the impact of pemetrexed in first-line maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic |
|---|---|
| Authors: | Gomes, Fabio1 (AUTHOR), Gilding, Niall2 (AUTHOR), Tan, Vivian2 (AUTHOR), Christoforou, Katerina2 (AUTHOR), Rule, Joanne2 (AUTHOR), Aziez, Amine3 (AUTHOR), Januszewski, Adam4 (AUTHOR), Minchom, Anna5 (AUTHOR) |
| Source: | Lung Cancer (01695002). 2024 Supplement 1, Vol. 190, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
